Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert Coffin"'
Autor:
Ke Liu, Steve H. Thorne, Daniel A. Saltzman, Peter Tattersall, Grant McFadden, Liang Deng, Balveen Kaur, Laura Evgin, Steve Fiering, Richard G. Vile, Sheryl Ruppel, Herbert Kim Lyerly, Robert M. Hoffman, James L. Gulley, Robert Coffin, Matthew Giacalone, Claudia Gravekamp, Ariel E. Marciscano, Halle Huihong Zhang, Neil S. Forbes, Eddie Moradian, Shibin Zhou, Hal Gunn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-24 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy
Autor:
Robert Coffin
Publikováno v:
Immunotherapy. 8:103-106
Interviewed by Ellen Clarke, Commissioning Editor, Future Science Group. Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999. He wa
Publikováno v:
Oncolytic Virotherapy
Oncolytic viruses that selectively lyse tumor cells with minimal damage to normal cells are a new area of therapeutic development in oncology. An attenuated herpesvirus encoding the granulocyte-macrophage colony stimulating factor (GM-CSF), known as
Autor:
Lynn E. Spitler, Howard L. Kaufman, Robert H.I. Andtbacka, Ai Li, Mohammed M. Milhem, Jason Chesney, Robert Coffin, Mark Shilkrut, Mark R. Middleton, Kevin J. Harrington, Frances A. Collichio, Neil Senzer, Keith A. Delman, Igor Puzanov, Sanjiv S. Agarwala, Thomas Amatruda
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM, a randomized Phase III trial o
Autor:
Keith A. Delman, Frances A. Collichio, Lynn E. Spitler, Ai Li, Merrick I. Ross, Igor Puzanov, Yining Ye, Thomas Amatruda, Robert H.I. Andtbacka, Robert Coffin, Howard L. Kaufman, Jennifer Gansert, Neil Senzer, Jason Chesney
Publikováno v:
Journal of Clinical Oncology. 32:9008a-9008a
9008a Background: T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune re...